Key points are not available for this paper at this time.
Use of systemic hormone therapy has decreased dramatically among U.S. women since the Women's Health Initiative results were published. But those results are being misapplied to treatment decisions for women in their 40s and 50s who have distressing vasomotor symptoms.
Manson et al. (Thu,) studied this question.